Pathogenesis-directed lupus therapeutics

PURPOSE OF REVIEW: Systemic lupus erythematosus (SLE) is a complex autoimmune disease characterized, posing significant challenges to effective management. This review summarizes current United States Food and Drug Administration -approved therapies and management guidelines of the American College of Rheumatology. RECENT FINDINGS: Contemporary SLE management is guided by organ systems involvement and disease severity. Discoveries of molecular mechanisms underlying disease pathogenesis have driven the development of targeted biologic therapies, including natural and engineered antibodies, chimeric antigen receptor-guided cell therapies, and T-cell engagers, transforming the therapeutic landscape of lupus. In addition to traditional B-cell and plasma cell surface targets, emerging molecular targets include transmembrane signaling molecules such as CD40L and intracellular organelles such as endosomes and mitochondria. SUMMARY: While antibody and cell-based biologic therapies target pathogenesis-driving molecules, they suppress key immune pathways and thus infection remains a leading cause of morbidity and mortality. Accordingly, this review also addresses nonpharmacologic strategies - such as dietary modifications - that may confer therapeutic benefit without increasing susceptibility to infection. With a rapidly expanding portfolio of mechanistically driven clinical trials, the future of SLE management appears increasingly promising.